Relmada Therapeutics (RLMD) Other Non Operating Income (2014 - 2020)
Relmada Therapeutics (RLMD) reported Other Non Operating Income of -$934919.0 for Q1 2020, down 125.13% year-over-year from $3.7 million in Q2 2019, and up 74.87% on a QoQ basis from -$3.7 million in Q2 2019.
Relmada Therapeutics (RLMD) has 7 years of Other Non Operating Income data on file, last reported at -$934919.0 in Q1 2020.
- Quarterly Other Non Operating Income fell 125.13% year-over-year to -$934919.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$4.7 million (down 305.07% YoY) and the FY2019 annual result came in at -$3.8 million, down 432.44% from the prior year.
- Other Non Operating Income advanced to -$934919.0 in Q1 2020 per RLMD's latest filing, from -$3.7 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $13.0 million in Q2 2016 and bottomed at -$3.8 million in Q4 2018.
- The 5-year median for Other Non Operating Income is -$66395.0 (2017), against an average of $530799.9.
- The widest annual swing landed in 2018, when Other Non Operating Income slumped 5486.48%; it then jumped 1559.55% in 2019.
- Tracing RLMD's Other Non Operating Income over 5 years: stood at $449041.0 in 2016, then slipped by 24.04% to $341106.0 in 2017, then tumbled by 1206.54% to -$3.8 million in 2018, then advanced by 1.45% to -$3.7 million in 2019, then soared by 74.87% to -$934919.0 in 2020.
- Per Business Quant, the three latest RLMD Other Non Operating Income figures stand at -$934919.0 (Q1 2020), -$3.7 million (Q2 2019), and $3.7 million (Q1 2019).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -934,919.00 |
| Jun 30, 2019 | -3.72 Mn |
| Mar 31, 2019 | 3.72 Mn |
| Dec 31, 2018 | -3.77 Mn |
| Sep 30, 2018 | -318,541.00 |
| Jun 30, 2018 | -789,443.00 |
| Mar 31, 2018 | -254,862.00 |
| Dec 31, 2017 | 341,106.00 |
| Sep 30, 2017 | -5,702.00 |
| Jun 30, 2017 | -66,395.00 |
| Mar 31, 2017 | 301,458.00 |
| Dec 31, 2016 | 449,041.00 |
| Sep 30, 2016 | -80,043.00 |
| Jun 30, 2016 | 13.04 Mn |
| Mar 31, 2016 | 54,559.00 |
| Dec 31, 2015 | 3.26 Mn |
| Sep 30, 2015 | 9.29 Mn |
| Jun 30, 2015 | 10.47 Mn |
| Mar 31, 2015 | 10,478.00 |
| Dec 31, 2014 | 9.84 Mn |
| Sep 30, 2014 | -26.12 Mn |
| Jun 30, 2014 | -8.39 Mn |
| Mar 31, 2014 | 7.33 Mn |